Core Insights - Alignment Healthcare, Inc. has been recognized by the Pharmacy Quality Alliance (PQA) for excellence in its Medicare Advantage prescription drug (MAPD) plan, with only 1.3% of 633 eligible contracts achieving this recognition, underscoring the award's significance [1][2] Group 1: Award Recognition - The 2025 PQA Laura Cranston Excellence in Quality Award was given to MAPDs with at least a 4.5-star Part D summary rating and a perfect 5-star rating on all five PQA medication measures [2] - Alignment Health was one of only two MAPDs to earn a perfect rating on five specific medication adherence measures, including diabetes medications and statins [2] Group 2: Commitment to Quality - Alignment has invested in quality through predictive technology and personalized concierge support to enhance medication adherence among seniors, addressing a common hurdle [4] - The company has received the PQA Excellence in Quality Award multiple times, including from 2018 to 2022, and is recognized for its commitment to advancing pharmacy care [4] Group 3: Company Overview - Alignment Health aims to empower seniors to live healthier lives through high-quality, low-cost care, utilizing a customized care model and a 24/7 concierge care team [6] - The company partners with trusted local providers to deliver coordinated care, maintaining a focus on serving seniors [6]

Core Insights - Vivani Medical, Inc. has successfully initiated the LIBERATE-1 study for its NPM-115 (exenatide implant) with full enrollment achieved, expecting top-line data in mid-2025 [1][4] - The company reported promising preclinical data for NPM-139 (semaglutide implant), indicating potential for once-yearly dosing comparable to existing treatments [1][3] - An additional $8.25 million in equity financing has been secured, ensuring financial stability into Q2 2026 to support ongoing development of NPM-115 and NPM-139 [1][3] Company Developments - Vivani transitioned to a clinical-stage biotechnology company in 2024, achieving significant milestones in its NPM-115 and NPM-139 programs [2] - The LIBERATE-1 study has successfully administered its first GLP-1 implant, addressing medication adherence challenges in chronic weight management and type 2 diabetes [4] - The company is advancing NPM-139 towards clinical phase development alongside the ongoing NPM-115 program [2][3] Financial Performance - As of December 31, 2024, Vivani reported a cash balance of $19.7 million, down from $22.0 million in 2023, primarily due to a net loss of $23.5 million [10] - Research and development expenses for Q4 2024 were $4.3 million, a decrease of 9% from $4.7 million in Q4 2023 [11] - General and administrative expenses increased by 43% to $2.1 million in Q4 2024 compared to $1.5 million in Q4 2023, attributed to higher professional services and stock-based compensation [12] Future Outlook - Key milestones for the LIBERATE-1 trial are anticipated, including the last subject implanted and top-line results expected in mid-2025 [15] - Vivani plans to file an Investigational New Drug Application for NPM-139 and advance its clinical trials [15] - The company is also preparing for the spin-off of its subsidiary Cortigent into an independent publicly traded company [5][15]